Viatris Inc (VTRS)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$1,805.7M
Cash & Equivalents
$388.3M
Quarterly Burn Rate
$18,679M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (12 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
PHENYTOIN
DILANTIN-30 |
APPROVED | — |
|
GABAPENTIN
NEURONTIN |
APPROVED | — |
|
SERTRALINE HYDROCHLORIDE
ZOLOFT |
APPROVED | — |
|
ZIPRASIDONE MESYLATE
GEODON |
APPROVED | — |
|
PHENYTOIN SODIUM
DILANTIN |
APPROVED | — |
|
DOXAZOSIN MESYLATE
CARDURA XL |
APPROVED | — |
|
ZOLPIDEM TARTRATE
EDLUAR |
APPROVED | — |
|
ZIPRASIDONE HYDROCHLORIDE
GEODON |
NDA | Abuse Potential, Actinic Keratoses, Actinic Keratosis, Acute Coronary Syndrome, Acute Exacerbation of Psychosis, Acute Mania, Acute Myocardial Infarction, Acute Pain, Adenomatous Polyposis Coli, Affective Psychosis, Bipolar, Allergic Rhinitis, Allergic Rhinitis Due to Allergens, Alzheimer's Disease, Amanita Poisoning, Amatoxin Poisoning, Angina, Angina Pectoris, Ankylosing Spondylitis, Anterior Ischemic Optic Neuropathy, Antibiotic Resistance, Anxiety, Anxiety Disorder, Arrhythmia, Arthritis, Gouty, Arthritis, Juvenile Rheumatoid, Arthritis, Psoriatic, Arthritis, Rheumatoid, Arthroscopy, Asthma, Asthma, Exercise-Induced, Atopic Dermatitis, Atrial Fibrillation, Atrophic Vaginitis, Back Pain, Basal Cell Carcinoma, Benign Prostatic Hyperplasia, Bioequivalence Study, Bipolar Disorder, Bipolar Disorder, Manic, Bipolar Mania, Blepharitis, Bone Neoplasms, Bowel Diseases, Inflammatory, Breast Cancer, Breast Neoplasms, Burns, Cancer, Carcinoma, Basal Cell, Cardiac Repolarization in Healthy Subjects, Cardiovascular, Ca |
|
ESTRADIOL
ELESTRIN |
NDA | Advanced Cancer, Advanced Malignancies, Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma, Advanced or Metastatic Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Atrophic Vaginitis Due to Menopause, Attention Deficit Hyperactivity Disorder, Brain Cancer, Brain Neoplasms, Broad Solid Tumor, Cancer, Carcinoma, Carcinoma, Non-Small-Cell Lung, Chronic Myeloid Leukemia, Clear-cell Metastatic Renal Cell Carcinoma, Colorectal Cancer, Esophageal Adenocarcinoma, Esophageal Cancer, Fasting, Gastric Cancer, Gastroesophageal-junction Cancer, Gastrointestinal Stromal Tumor, Glaucoma, Open-Angle, HCC, Head & Neck Cancer, Head and Neck Cancer, Healthy Postmenopausal Women, Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases, Hepatitis B, Hepatocellular Carcinoma, HIV Infections, Hodgkin's Disease, Hypogonadotropic Hypogonadism, Juvenile Idiopathic Arthritis, Liver Cancer, Lung Cancer, Lymphoma, Malignant Tumors, Melanoma, Mesothelioma, Me |
|
TOBRAMYCIN
TOBI PODHALER |
NDA | — |
|
HYDROCORTISONE ACETATE
CORTIFOAM |
NDA | — |
|
ALPROSTADIL
MUSE |
NDA | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-07-30 | Pdufa | — |
| 2026-10-01 | Phase1 Readout | — |
| 2026-10-31 | Phase3 Readout | — |
| 2026-10-31 | Phase3 Readout | — |
| 2026-11-30 | Phase2 Readout | — |
| 2026-12-01 | Phase3 Readout | — |
| 2027-05-01 | Phase3 Readout | — |
Active Clinical Trials (12)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07606625 | Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment | PHASE4 | Recruiting | 65 |
| NCT06135324 | Impairments That Affect Correct Inhaler Use in COPD | OTHER | Active Not Recruiting | 500 |
| NCT06471088 | Safety and Efficacy Evaluation of <Dovprela Tablets 200 mg> by Post-marketing Surveillance | OTHER | Recruiting | 100 |
| NCT07231796 | Naldemedine in Clinical Practice in Cancer Patients With Opioid Induced CONstipation: Clinical Outcomes and Patient Expe... | OTHER | Recruiting | 100 |
| NCT07201129 | A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatm... | PHASE3 | Recruiting | 300 |
| NCT05648500 | A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythemat... | PHASE3 | Active Not Recruiting | 470 |
| NCT06475742 | Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus | PHASE3 | Enrolling By Invitation | 680 |
| NCT04957719 | Selatogrel Outcome Study in Suspected Acute Myocardial Infarction | PHASE3 | Enrolling By Invitation | 25,000 |
| NCT05672576 | A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosu... | PHASE3 | Active Not Recruiting | 451 |
| NCT06672016 | Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential | PHASE3 | Active Not Recruiting | 1,630 |
| NCT07365904 | Investigating Ovulation Inhibition for Use as a Contraceptive | PHASE2 | Recruiting | 60 |
| NCT07266090 | A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Particip... | PHASE2 | Active Not Recruiting | 15 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.